Troriluzole

• CAT Number: I017161
• CAS Number: 1926203-09-9
• Molecular Formula: C15H16F3N5O4S
• Molecular Weight: 419.38
• Purity: ≥95%
• Synonyms: 2-amino-N-[2-[methyl-[2-oxo-2-[[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]amino]ethyl]amino]-2-oxoethyl]acetamide
• InChI: InChI=1S/C15H16F3N5O4S/c1-23(13(26)6-20-11(24)5-19)7-12(25)22-14-21-9-3-2-8(4-10(9)28-14)27-15(16,17)18/h2-4H,5-7,19H2,1H3,(H,20,24)(H,21,22,25)
• InChIKey: YBZSGIWIPOUSHY-UHFFFAOYSA-N
• SMILES: CN(CC(=O)NC1=NC2=C(S1)C=C(C=C2)OC(F)(F)F)C(=O)CNC(=O)CN

Troriluzole is an investigational prodrug of riluzole, developed to enhance the treatment of neurological disorders, including Alzheimer’s disease and generalized anxiety disorder. It is designed to modulate glutamate, a neurotransmitter involved in cognitive and motor functions. By enhancing the brain’s regulation of glutamate, Troriluzole aims to reduce neurotoxicity and improve neurological outcomes. The prodrug formulation improves riluzole’s bioavailability and provides more consistent therapeutic levels in the body. Troriluzole’s potential to protect neurons and improve synaptic function makes it a promising candidate in the treatment of neurodegenerative diseases and related conditions, though it remains under clinical investigation.